Top Ten most popular articles on Pharmafile.com this week!
pharmafile | July 19, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AMAL Therapeutics, Alzheimer's Ebola, Amgen, AstraZeneca, EMA, FDA, Novartis, pharma
On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 after those taking it seemed to get worse. The news comes as yet another setback in the field as researchers saw another drug fail to take ground against the disease.
In other news AstraZeneca said it would switch its entire fleet to electric by 2030 as it pledged its commitment to the EV100 group. The Anglo Swedish multinational also received an orphan drug designation (ODD) for Imfinzi. However they failed to get FDA approval for diabetes drug Farxiga in patients with Type 1 form of the disease.
Meanwhile Boehringer bought cancer vaccine firm AMAL Therapeutics while the FDA and EMA fully implemented the mutual recognition agreement between the US and the EU. In other news the WHO declared a global public health emergency in the Congo over the outbreak of Ebola. For all this and more check out this week’s top 10 at Pharmafile.com!
10. Novartis CEO sets aside $700 million to settle bribery lawsuit
Vas Narasimhan, Novartis’ CEO, has set aside $700 million to settle a bribery lawsuit in the United States.
9. Feature: Darius Hughes, Head of Vaccines Business Unit UK, Pfizer
“Vaccines provide a unique opportunity to have a positive effect on hundreds of thousands of people” – Darius Hughes, Head of Vaccines Business Unit UK, Pfizer
8. WHO declares global public health emergency over Ebola outbreak in Congo
The UN health organisation has declared a global public health emergency over the Ebola outbreak, after an emergency committee meeting in Geneva.
7. FDA and EMA fully implement mutual recognition agreement between US and EU
The FDA has recognised Slovakia’s ability to carry out inspections of manufacturing facilties.
6. GSK teams up with Strathclyde and University of Nottingham
GlaxoSmithKline has teamed up with the University of Nottingham and the University of Strathclyde for a five-year partnership aimed at promoting new medical research.
5. AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes
The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in adults with Type 1 diabetes who haven’t been able to control their condition with insulin alone.
4. Boehringer buys cancer vaccine company AMAL Therapeutics for €325 million
Boehringer Ingelheim has bought Swiss biotech AMAL Therapeutics, a company focused on cancer immunotherapy and cancer vaccines.
3. AstraZeneca’s Imfinzi gets orphan drug designation from FDA
AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC).
2. AstraZeneca to switch entire fleet to electric vehicles by 2030
AstraZeneca has revealed plans to use only electric vehicles by 2030.
1. Novartis and Amgen halt trials into Alzheimer’s drug after patients get worse
Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions worsened after taking the drug.
Related Content
FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …
